SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 66 filers reported holding SYROS PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $388,000 | +84.8% | 42,419 | +12.7% | 0.00% | – |
| Q4 2018 | $210,000 | -76.6% | 37,651 | -50.0% | 0.00% | -100.0% |
| Q3 2018 | $896,000 | +131.5% | 75,302 | +98.8% | 0.00% | – |
| Q2 2018 | $387,000 | +31.2% | 37,880 | +66.7% | 0.00% | – |
| Q1 2018 | $295,000 | +33.5% | 22,718 | 0.0% | 0.00% | – |
| Q4 2017 | $221,000 | -33.8% | 22,718 | 0.0% | 0.00% | – |
| Q3 2017 | $334,000 | -8.7% | 22,718 | 0.0% | 0.00% | -100.0% |
| Q2 2017 | $366,000 | +363.3% | 22,718 | +360.5% | 0.00% | – |
| Q1 2017 | $79,000 | +31.7% | 4,933 | 0.0% | 0.00% | – |
| Q4 2016 | $60,000 | -11.8% | 4,933 | 0.0% | 0.00% | – |
| Q3 2016 | $68,000 | – | 4,933 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
| Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
| Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
| Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
| EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
| Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
| Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
| Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
| Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |